BACKGROUND: The adverse impact of Plasmodium vivax on child health beyond acute febrile illness is poorly studied. The effect of vivax malaria on child growth was evaluated and compared with diarrhoeal disease and non-specific fever. METHODS: Using data from a 43-month longitudinal cohort of children 0-72 months of age (n = 442) in the Peruvian Amazon, ponderal and linear growth velocities over 2-, 4- and 6-month periods were examined using longitudinal models and related to the incidence of disease during the same period. RESULTS: An episode of vivax malaria led to 138.6 g (95% confidence interval (CI) 81.9-195.4), 108.6 g (62.8-153.2) and 61 g (20.9-101.1) less weight gain over 2-, 4- and 6-month intervals, respectively. These deficits were larger than both diarrhoea (21.9, 17.2 and 13.8 g less weight gain, respectively) and fever (39.0, 30.3 and 25.6 g less weight gain, respectively). An incident episode of vivax also led to 0.070 cm (0.004-0.137) and 0.083 cm (0.015-0.151) less linear growth over 4 and 6 months, respectively, which were also larger than deficits from diarrhoea (0.029 and 0.028 cm, respectively) and fever (not associated with linear growth deficits). Despite the larger effect of P. vivax incident episodes on growth of a particular child, diarrhoeal disease had a larger cumulative impact on growth deficits as diarrhoeal incidence rates in this community are >10-fold higher than vivax malaria. CONCLUSIONS: Disease control measures for vivax malaria and diarrhoeal disease have the potential to improve the growth of children in endemic areas.
BACKGROUND: The adverse impact of Plasmodium vivax on child health beyond acute febrile illness is poorly studied. The effect of vivax malaria on child growth was evaluated and compared with diarrhoeal disease and non-specific fever. METHODS: Using data from a 43-month longitudinal cohort of children 0-72 months of age (n = 442) in the Peruvian Amazon, ponderal and linear growth velocities over 2-, 4- and 6-month periods were examined using longitudinal models and related to the incidence of disease during the same period. RESULTS: An episode of vivax malaria led to 138.6 g (95% confidence interval (CI) 81.9-195.4), 108.6 g (62.8-153.2) and 61 g (20.9-101.1) less weight gain over 2-, 4- and 6-month intervals, respectively. These deficits were larger than both diarrhoea (21.9, 17.2 and 13.8 g less weight gain, respectively) and fever (39.0, 30.3 and 25.6 g less weight gain, respectively). An incident episode of vivax also led to 0.070 cm (0.004-0.137) and 0.083 cm (0.015-0.151) less linear growth over 4 and 6 months, respectively, which were also larger than deficits from diarrhoea (0.029 and 0.028 cm, respectively) and fever (not associated with linear growth deficits). Despite the larger effect of P. vivax incident episodes on growth of a particular child, diarrhoeal disease had a larger cumulative impact on growth deficits as diarrhoeal incidence rates in this community are >10-fold higher than vivax malaria. CONCLUSIONS: Disease control measures for vivax malaria and diarrhoeal disease have the potential to improve the growth of children in endemic areas.
Authors: Baback Roshanravan; Elina Kari; Robert H Gilman; Lilia Cabrera; Ellen Lee; John Metcalfe; Maritza Calderon; Andres G Lescano; Sonia H Montenegro; Carlos Calampa; Joseph M Vinetz Journal: Am J Trop Med Hyg Date: 2003-07 Impact factor: 2.345
Authors: Feiko O ter Kuile; Dianne J Terlouw; Simon K Kariuki; Penelope A Phillips-Howard; Lisa B Mirel; William A Hawley; Jennifer F Friedman; Ya Ping Shi; Margarette S Kolczak; Altaf A Lal; John M Vulule; Bernard L Nahlen Journal: Am J Trop Med Hyg Date: 2003-04 Impact factor: 2.345
Authors: William Checkley; Leonardo D Epstein; Robert H Gilman; Lilia Cabrera; Robert E Black Journal: Am J Epidemiol Date: 2003-01-15 Impact factor: 4.897
Authors: Márcia A Alexandre; Cynthia O Ferreira; André M Siqueira; Belisa L Magalhães; Maria Paula G Mourão; Marcus V Lacerda; Maria das Gracas C Alecrim Journal: Emerg Infect Dis Date: 2010-10 Impact factor: 6.883
Authors: Francesca Schiaffino; Gwenyth O Lee; Maribel Paredes-Olortegui; Lilia Cabrera; Pablo Penataro-Yori; Robert H Gilman; Margaret N Kosek Journal: Am J Perinatol Date: 2018-12-24 Impact factor: 1.862
Authors: Regina I Ejemot-Nwadiaro; John E Ehiri; Dachi Arikpo; Martin M Meremikwu; Julia A Critchley Journal: Cochrane Database Syst Rev Date: 2021-01-06
Authors: Margaret Kosek; Pablo P Yori; Robert H Gilman; Maritza Calderon; Mirko Zimic; Raul Chuquiyauri; Cesar Jeri; Viviana Pinedo-Cancino; Michael A Matthias; Alejandro Llanos-Cuentas; Joseph M Vinetz Journal: Am J Trop Med Hyg Date: 2012-04 Impact factor: 2.345
Authors: James A Platts-Mills; Sudhir Babji; Ladaporn Bodhidatta; Jean Gratz; Rashidul Haque; Alexandre Havt; Benjamin Jj McCormick; Monica McGrath; Maribel Paredes Olortegui; Amidou Samie; Sadia Shakoor; Dinesh Mondal; Ila Fn Lima; Dinesh Hariraju; Bishnu B Rayamajhi; Shahida Qureshi; Furqan Kabir; Pablo P Yori; Brenda Mufamadi; Caroline Amour; J Daniel Carreon; Stephanie A Richard; Dennis Lang; Pascal Bessong; Esto Mduma; Tahmeed Ahmed; Aldo Aam Lima; Carl J Mason; Anita Km Zaidi; Zulfiqar A Bhutta; Margaret Kosek; Richard L Guerrant; Michael Gottlieb; Mark Miller; Gagandeep Kang; Eric R Houpt Journal: Lancet Glob Health Date: 2015-07-19 Impact factor: 26.763
Authors: Regina I Ejemot-Nwadiaro; John E Ehiri; Dachi Arikpo; Martin M Meremikwu; Julia A Critchley Journal: Cochrane Database Syst Rev Date: 2015-09-03
Authors: Stephanie A Richard; Leah J Barrett; Richard L Guerrant; William Checkley; Mark A Miller Journal: Clin Infect Dis Date: 2014-11-01 Impact factor: 9.079
Authors: James A Platts-Mills; Benjamin J J McCormick; Margaret Kosek; William K Pan; William Checkley; Eric R Houpt Journal: Clin Infect Dis Date: 2014-11-01 Impact factor: 9.079
Authors: Stephanie A Richard; Robert E Black; Robert H Gilman; Richard L Guerrant; Gagandeep Kang; Claudio F Lanata; Kåre Mølbak; Zeba A Rasmussen; R Bradley Sack; Palle Valentiner-Branth; William Checkley Journal: J Nutr Date: 2014-04-03 Impact factor: 4.798